TABLE 1.
Demographic and Clinical Features of Enrolled Patients
| Group 1: Biologic Therapy | Group 2: No Biologic Therapy | P† | |
|---|---|---|---|
| Patients, n | 124 | 119 | — |
| Male, n (%) | 79 (63.7) | 63 (52.9) | 0.093 |
| Age, y (mean ± SD) | 45.9 ± 14.5 | 49.0 ± 16.1 | 0.121 |
| Employed, n (%) | 101 (81.5) | 84 (70.6) | 0.052 |
| Comorbidities, n (%)* | 43 (34.7) | 50 (42.0) | 0.291 |
| Duration of disease, y (mean ± SD) | 10.8 ± 8.6 | 14.5 ± 11.3 | 0.004 |
| Active disease, n (%) | 30 (24.2) | 19 (16.0) | 0.150 |
| Therapy, n (%) | |||
| None | 0 (0.0) | 26 (21.8) | NA |
| 5-aminosalicylates | 50 (40.3) | 77 (64.7) | 0.001 |
| Low-bioavailability steroids | 2 (1.6) | 4 (3.4) | 0.439 |
| Systemic steroids | 3 (2.4) | 5 (4.2) | 0.493 |
| Thiopurines | 2 (1.6) | 15 (12.6) | 0.001 |
| Infliximab | 25 (20.2) | — | NA |
| Adalimumab | 38 (30.6) | — | NA |
| Golimumab | 12 (9.7) | — | NA |
| Vedolizumab | 26 (21.0) | — | NA |
| Ustekinumab | 13 (10.5) | — | NA |
| Etrolizumab | 2 (1.6) | — | NA |
| Mirikizumab | 3 (2.4) | — | NA |
| Risankizumab | 4 (3.2) | — | NA |
| Infliximab plus azathioprine | 1 (0.8) | — | NA |
| COVID-19, n (%) | 2 (1.6) | 9 (7.6) | 0.031 |
| Sure | 0 (0.0) | 1 (0.8) | 0.490 |
| Likely | 2 (1.6) | 8 (6.7) | 0.056 |
| Pneumonia | 1 (0.8) | 4 (3.4) | 0.206 |
| Hospitalization | 1 (0.8) | 1 (0.8) | 1.000 |
*At least 1: coronary artery disease, arterial hypertension, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney failure, neoplasms, immune-mediated inflammatory disease.
†Student t test or Fisher exact test.
NA indicates not applicable.